Novavax (NVAX) Misses Q4 EPS by 1c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.68 +1.57%
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Research and development: 52.98M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Note: EPS may not be comparable
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $7.98 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- First Tracks Biotherapeutics, Inc. (TRAX) Misses Q3 EPS by 88c
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
